ClinicalTrials.gg
CompletedNCT06152042Updated Aug 28, 2026

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

A Phase 2 interventional study of BMF-219 in Type 1 Diabetes Mellitus, sponsored by Biomea Fusion Inc.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Biomea Fusion Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
651st of 1,242
37 · median 40
Started
2023
with 65 others
Phase 2
188 of 1,458
24 open now
Registered
1,267th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 651st largest by enrollment of the 1,242 interventional ones that give a count, is one of 66 that started in 2023, is one of 188 in phase 2, and was the 1,267th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Read the detailed description

Study COVALENT-112 is a 52-week, Phase 2 trial designed to examine beta-cell function, insulin sensitivity, and both glucose and lipid metabolism in participants with T1D treated with BMF-219. BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, age ≥18 and ≤70 years.
  2. Diagnosed with stage 3 T1D within the following timeframes:

    • Part 1 Cohort 1: Participants diagnosed within 3 years prior to screening.
    • Part 1 Cohort 2: Participants diagnosed between 3 to 15 years prior to screening
    • Part 2 : Participants diagnosed within 15 years prior to screening.
  3. Treated with insulin only for at least 2 months prior to screening and proficient in the following in the opinion of the investigator:

    • Counting carbohydrates
    • Adjusting meal and correction boluses based on glucose readings with a stable insulin/carbohydrate ratio as well as correction factors
    • Adjusting insulin and dietary therapy during special situations (eg, exercise, stress, intermittent diseases)
  4. ≥6.5 and ≤10.0% at screening.
  5. Fasting or stimulated C-peptide Concentration at Screening as follows:

    • C-peptide concentration ≥0.2 nmol/L if diagnosed within 3 years prior to screening.
    • C-peptide concentration ≥0.08 nmol/L if diagnosed between 3 and 15 years prior to screening.
  6. Documented history of at least 1 T1D1-related autoantibody.
  7. If treated with lipid-lowering therapy, the dose must be stable for at least 30 days prior to screening.
  8. Men and women of must use adequate measures for the duration of the trial and at least 90 days after discontinuing study treatment.
  9. Women who are not pregnant or lactating.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of MODY, T2D or any other subtype of diabetes mellitus other than T1D.
  2. Have had recurrence (≥2 episodes) of severe hypoglycemia
  3. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
  4. Use of diabetes medications except insulin within 2 months prior to screening.
  5. Any significant cardiovascular disease or prolongation within the last 6 months prior to screening.
  6. Participants with fasting triglyceride ≥500 mg/dL.
  7. Have an \<60 mL/min/1.73 m2 by the CKDEPI Creatinine Equation at screening.
  8. Impaired liver function, defined as screening or ALT >1.5 × , Total >1.5 × ULN with the exception of Gilbert's Syndrome.
  9. History of acute or chronic pancreatitis, complete pancreatectomy or pancreas transplants.
  10. Serum lipase and/or amylase above 1.5 x ULN.
  11. Known positive test for , surface antigen and COVID-19.
  12. Diagnosis of, or treatment for, any cancer within the last 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy.
  13. Active (symptomatic) celiac disease.
  14. History of stomach or intestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs.
  15. History of cirrhosis.
  16. Currently participating in a formal weight loss program and/or are currently using any drugs for weight management within 2 months of screening.
  17. Use of Proton pump inhibitors (PPIs) is prohibited.
  18. Treatment with a moderate or strong inhibitor, inducer, or substrate within a week prior to dosing on Day 1.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Part 1

    Part 1 uses a randomized, open-label design with parallel assignment between 2 treatment arms in each cohort. The Part 1 Eligible participants will be randomly assigned by cohort to 1 of 2 treatment arms: * Cohort 1: Participants with T1D diagnosed within 3 years with C-peptide concentration ≥0.2 nmol/L * Arm A: BMF-219 100 mg QD for 12 weeks * Arm B: BMF-219 200 mg QD for 12 weeks * Cohort 2: Participants with T1D diagnosed between 3 to 15 years with C-peptide concentration ≥0.08 nmol/L. * Arm A: BMF-219 100 mg QD for 12 weeks * Arm B: BMF-219 200 mg QD for 12 weeks

    Drug: BMF-219

  • Experimental
    Part 2

    Part 2 Part 2 uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. Eligible participants will be randomly assigned to 1 of 3 arms using a 1:1:1 ratio: * Arm A: BMF-219 100 mg QD for 12 weeks * Arm B: BMF-219 200 mg QD for 12 weeks

    Drug: BMF-219

  • Placebo comparator
    Placebo Comparator

    Part 2 Study Double Blind Arm C matching placebo for 12 weeks.

    Drug: BMF-219

Interventions

  • BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

06

What researchers measure

Primary outcomes

  1. To assess the effect on endogenous insulin secretion

    Mean change from baseline in stimulated C-peptide AUC.

    Time frame: 26 Weeks

Secondary outcomes

  1. To assess the effect on endogenous insulin secretion

    Maximum stimulated C-peptide: the highest value at any time point during the 4-hour MMTT.

    Time frame: 26 Weeks

  2. To assess the effect on additional glycemic parameters

    Mean change from baseline in HbA1c.

    Time frame: 26 Weeks of treatment

  3. To assess the effect on additional glycemic parameters

    Mean change from baseline in FPG.

    Time frame: 26 Weeks

  4. To assess hypoglycemia events

    Percentage of participants with hypoglycemic episodes (with confirmed self-plasma glucose monitoring) including level 2 hypoglycemic events (\<54 mg/dL regardless of symptoms) and level 3 (severe) hypoglycemia across different timepoints.

    Time frame: 26 weeks

  5. To assess the effect on insulin doses

    Change from baseline in mean daily insulin dosing.

    Time frame: 26 Weeks

  6. Rate of symptomatic hypoglycemic episodes

    Evaluation and comparison of the number of symptomatic (both minor and severe) hypoglycemic episodes with BMF-219 vs placebo during the study.

    Time frame: 26 Weeks and during study duration

  7. Incidence of adverse events

    Evaluation and comparison of the number of adverse events with BMF-219 vs placebo during the study.

    Time frame: 26 Weeks and during study duration

07

Study locations

11 sites
  • Oceanic Research Group
    North Miami Beach, Florida 33169, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28577, United States
  • Alliance for Multispecialty Research, LLC.
    Norman, Oklahoma 73069, United States
  • University Diabetes & Endocrine Consultants
    Chattanooga, Tennessee 37411, United States
  • Velocity Clinical Research
    Dallas, Texas 75230, United States
  • Texas Diabetes & Endocrinology
    Round Rock, Texas 78681, United States
  • Diabetes & Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Dr. T.G Elliott Inc. dba BC Diabetes
    Vancouver, British Columbia, Canada
  • Centricity Research
    Toronto, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in May 2025, 16 months.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 30, 2023
StartActual
Dec 28, 2023
Primary completionActual
May 20, 2025
CompletionActual
Jul 18, 2025
Results delay requested
May 6, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06152042
Lead sponsor
Biomea Fusion Inc.
Responsible party
Sponsor
First posted
Nov 30, 2023
Start date
Dec 28, 2023
Primary completion
May 20, 2025
Completion
Jul 18, 2025
Last update
Aug 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icovamenib

Start the discussion